Sugi Predict

Sugi Predict / Targets / LIG1

LIG1

DNA ligase 1 · P18858 · LIG1 on Sugi Atlas →

5,351 patent compounds predicted against LIG1, 3,936 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL914342 SCHEMBL914342 0.49 2/20
SCHEMBL914343 SCHEMBL914343 0.49 2/20
SCHEMBL3631238 SCHEMBL3631238 0.48 2/20
SCHEMBL3631239 SCHEMBL3631239 0.48 2/20
Acetic Acid Acetic Acid (SCHEMBL924390) 0.48 2/20
Acetic Acid Acetic Acid (SCHEMBL924391) 0.48 2/20
SCHEMBL1267091 SCHEMBL1267091 0.35 2/20
SCHEMBL1568564 SCHEMBL1568564 1.00 1/20
SCHEMBL1742133 SCHEMBL1742133 1.00 1/20
SCHEMBL2723219 SCHEMBL2723219 1.00 1/20
SCHEMBL1908387 SCHEMBL1908387 0.79 1/20
SCHEMBL36215 SCHEMBL36215 0.76 1/20
SCHEMBL2127248 SCHEMBL2127248 0.74 1/20
Benzophenone Benzophenone (SCHEMBL178099) 0.73 1/20
Bicarbonate Bicarbonate (SCHEMBL376894) 0.73 1/20
SCHEMBL958440 SCHEMBL958440 0.71 1/20
SCHEMBL1947873 SCHEMBL1947873 0.71 1/20
SCHEMBL3483879 SCHEMBL3483879 0.71 1/20
Formaldehyde Formaldehyde (SCHEMBL588098) 0.70 1/20
SCHEMBL40310 SCHEMBL40310 0.69 1/20

Clinical trials — most relevant to LIG1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency PHASE2/PHASE3RECRUITING
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation PHASE2UNKNOWN
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation PHASE2UNKNOWN
Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA) PHASE1/PHASE2COMPLETED
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma PHASE2COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Phase II ABT-888 With Cyclophosphamide PHASE2COMPLETED
Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial) PHASE2UNKNOWN
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies PHASE1/PHASE2RECRUITING
Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects PHASE2COMPLETED
Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL) PHASE2COMPLETED
PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers PHASE1/PHASE2COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors PHASE1COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors PHASE1COMPLETED
AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer PHASE1COMPLETED
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma PHASE1RECRUITING
ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems PHASE1WITHDRAWN
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer PHASE1COMPLETED
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers PHASE1COMPLETED
Chromosomal Translocations in Chandigarh Police nanCOMPLETED
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients nanCOMPLETED
The Genetic and the Functional Study of DNA Repair System and the Susceptibility to Rheumatoid Arthritis nanCOMPLETED
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1 nanRECRUITING
Application of Genetic Polymorphisms of DNA Repair in The Prediction of Prostate Cancer Susceptibility and Its Clinical Outcome nanUNKNOWN
DNA Repair in Patients With Stable Angina. nanUNKNOWN
Patient-derived Glioma Stem Cell Organoids nanACTIVE_NOT_RECRUITING
Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581 nanCOMPLETED
DNA Repair Genes and Outcomes in Patients With Stage III NSCLC nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a LIG1 binder may also engage these)

ProteinNameSimilarity
P37913 — 1.000 P37913 →
Q9JHY8 — 0.991 Q9JHY8 →
Q63186 — 0.970 Q63186 →
P41111 — 0.967 P41111 →
EIF2B4 Translation initiation factor eIF2B subunit delta 0.967 landscape →
TRMT1 tRNA (guanine(26)-N(2))-dimethyltransferase 0.966 landscape →
Q8BMI3 — 0.965 Q8BMI3 →
PLCB3 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-3 0.965 landscape →
P51432 — 0.964 P51432 →
Q3T058 — 0.964 Q3T058 →
P51892 — 0.964 P51892 →
Q61749 — 0.964 Q61749 →
Q9JLV6 — 0.964 Q9JLV6 →
P18887 — 0.964 P18887 →
F1QWK4 — 0.963 F1QWK4 →
Q3TX08 — 0.963 Q3TX08 →
Q60596 — 0.962 Q60596 →
O54935 — 0.962 O54935 →
Q8BML1 — 0.962 Q8BML1 →
MAP4K2 Mitogen-activated protein kinase kinase kinase kinase 2 0.961 landscape →
P97386 — 0.960 P97386 →
F1N2W9 — 0.960 F1N2W9 →
Q91YU8 — 0.959 Q91YU8 →
Q8CG07 — 0.959 Q8CG07 →
Q3UFQ8 — 0.959 Q3UFQ8 →
Q9NRL3 — 0.958 Q9NRL3 →
NOM1 Nucleolar MIF4G domain-containing protein 1 0.958 landscape →
LIG3 DNA ligase 3 0.958 landscape →
P51400 — 0.958 P51400 →
Q5XHY1 — 0.958 Q5XHY1 →